Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriasis
Interventions: Clobetasol Propionate, 0.05%, Clobetasol propionate, 0.05% Spray; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Cedar Knolls, New Jersey

Conditions: Psoriasis, Plaque Psoriasis
Interventions: MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Psoriasis Vulgaris
Interventions: Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene, Topical suspension vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 59
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Anaheim, California + 50 more

Conditions: Plaque Psoriasis
Interventions: CF101, Placebo; Drug
Lead sponsor: Can-Fite BioPharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit; Drug · Procedure
Lead sponsor: Jaehwan Kim; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Sacramento, California • New York, New York

Conditions: Plaque Psoriasis
Interventions: Halobetasol Topical Foam; Drug
Lead sponsor: Mayne Pharma International Pty Ltd; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Hialeah, Florida • Saint Joseph, Missouri

Conditions: Plaque Psoriasis
Interventions: TLL018 tablets; Drug
Lead sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: Psoriasis
Interventions: Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept; Procedure · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: D-2570 Tablet, Placebo Tablets; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 16 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions: Pharmacokinetics of certolizumab pegol; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma

Conditions: Psoriasis
Interventions: Ustekinumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: Clobetasol Propionate 0.05% Spray, Clobetasol Propionate 0.05% Foam; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Vallejo, California • St Louis, Missouri

Conditions: Psoriasis, Arthritic
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more

Conditions: Plaque Psoriasis
Interventions: IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion, IDP-118 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 18
States / cities: Encino, California • San Diego, California • Santa Rosa, California + 15 more

Conditions: Psoriasis
Interventions: Placebo, 50 mg etanercept, 80 mg ixekizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more

Conditions: Arthritis, Psoriatic
Interventions: golimumab, Placebo; golimumab; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 18
States / cities: Huntsville, Alabama • La Jolla, California • Upland, California + 15 more

Conditions: Plaque Psoriasis
Interventions: DSXS; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Plaque-type Psoriasis
Interventions: COL-121, 50 µg/g Calcipotriene Ointment, Placebo; Drug
Lead sponsor: Deltanoid Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Fremont, California • Los Angeles, California • San Diego, California + 17 more

Conditions: Moderate to Severe Chronic Plaque Psoriasis
Interventions: DMB-3115, Stelara; Drug
Lead sponsor: Dong-A ST Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Norman, Oklahoma • West Jordan, Utah

Conditions: Generalized Pustular Psoriasis
Interventions: Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab, Standard of Care (SOC), Imsidolimab 750 mg IV/200 mg SC; Drug · Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis
Interventions: Etanercept / Autoinjector A; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more

Conditions: Psoriasis
Interventions: Text reminder; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Plaque Type Psoriasis
Interventions: GP2017 Adalimumab, Humira ® Adalimumab; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 60 more

Conditions: Psoriasis
Interventions: M518101; Drug
Lead sponsor: Maruho North America Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Mesa, Arizona • Bakersfield, California • Los Angeles, California + 26 more

Search by objective public record fields.

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

Trial of CF101 to Treat Patients With Psoriasis

Risankizumab Long-term Remission Study

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis

Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

Deucravacitinib Adherence Study

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis